Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
EGT0001474
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2 focused on measuring Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
- Male or females between the ages of 18 to 70 diagnosed with Type 2 diabetes.
- Body mass Index (BMI) between 18 kg/m2 and 37 kg/m2.
- HbA1c levels between 6.5 and 9.0 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or 6.2-9.0% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1% and fasting plasma glucose between 110 and 240 mg/dL (inclusive) while on diabetic medications.
- If taking drugs for diabetes, must be medically able and willing to discontinue diabetes medications for the duration of the study.
- Female subjects must be surgically sterilized or postmenopausal.
- Non-smoker for at least 3 months.
- Negative alcohol screen.
Exclusion Criteria:
- Type 1 diabetes.
- Use of insulin therapy or oral antidiabetic medication other than metformin, sitagliptin or a sulfonylurea.
- Sitting blood pressure above 150/95 mmHg on 2 evaluations at least 10 minutes apart at screening.
- Treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.
- Previous treatment with EGT0001474.
- Vaccination within 30 days prior to the first dose of study medication.
Sites / Locations
- dgd Research Inc., a Cetero Research Company
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
EGT0001474
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Safety and Tolerability of EGT0001474
Safety and tolerability were measured in terms of the number of mild, moderate and severe adverse events experienced by any participants.
AUC 0-t
Area under the plasma concentration-time curve from time 0 to time t
AUC0-24
Area under the plasma concentration-time curve from time 0 to hour 24
AUC Inf
Area under the plasma concentration-time curve from time 0 to infinity
Cmax
Maximum plasma concentration
Tmax
Time of maximum plasma concentration
λz
Terminal phase rate constant
t1/2
Apparent terminal half life
CL/F
The apparent rate of oral clearance of EGT0001474.Oral clearance was defined as rate of drug removal from the body after oral administration.
Vz/F
Apparent volume of distribution
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00924053
Brief Title
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
Official Title
A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theracos
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how much of the drug gets into the blood and how long it takes the body to get rid of it) of single doses of EGT0001474 given to patients with Type 2 diabetes. The study will also evaluate how EGT0001474 affects the amount of glucose produced by the body in the urine.
Detailed Description
EGT0001474 is a compound that may inhibit the effect of other compounds in the body known as sugar transporters. The use of EGT0001474 may enhance the elimination of glucose from the blood by increasing the amount of urine produced. This would help prevent an abnormal decrease in blood sugar (hypoglycemia) both during fasting and after meals without increasing insulin secretion (which may result in weight gain or an abnormal increase in blood sugar known as Type 2 diabetes).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
Keywords
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
EGT0001474
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
EGT0001474
Other Intervention Name(s)
Human SGLT2 inhibitor
Intervention Description
Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Human SGLT2 inhibitor
Intervention Description
Placebo capsules to match EGT0001474
Primary Outcome Measure Information:
Title
Safety and Tolerability of EGT0001474
Description
Safety and tolerability were measured in terms of the number of mild, moderate and severe adverse events experienced by any participants.
Time Frame
25 days
Title
AUC 0-t
Description
Area under the plasma concentration-time curve from time 0 to time t
Time Frame
3 days
Title
AUC0-24
Description
Area under the plasma concentration-time curve from time 0 to hour 24
Time Frame
3 days
Title
AUC Inf
Description
Area under the plasma concentration-time curve from time 0 to infinity
Time Frame
3 days
Title
Cmax
Description
Maximum plasma concentration
Time Frame
3 days
Title
Tmax
Description
Time of maximum plasma concentration
Time Frame
3 days
Title
λz
Description
Terminal phase rate constant
Time Frame
3 days
Title
t1/2
Description
Apparent terminal half life
Time Frame
3 days
Title
CL/F
Description
The apparent rate of oral clearance of EGT0001474.Oral clearance was defined as rate of drug removal from the body after oral administration.
Time Frame
3 days
Title
Vz/F
Description
Apparent volume of distribution
Time Frame
3 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or females between the ages of 18 to 70 diagnosed with Type 2 diabetes.
Body mass Index (BMI) between 18 kg/m2 and 37 kg/m2.
HbA1c levels between 6.5 and 9.0 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or 6.2-9.0% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1% and fasting plasma glucose between 110 and 240 mg/dL (inclusive) while on diabetic medications.
If taking drugs for diabetes, must be medically able and willing to discontinue diabetes medications for the duration of the study.
Female subjects must be surgically sterilized or postmenopausal.
Non-smoker for at least 3 months.
Negative alcohol screen.
Exclusion Criteria:
Type 1 diabetes.
Use of insulin therapy or oral antidiabetic medication other than metformin, sitagliptin or a sulfonylurea.
Sitting blood pressure above 150/95 mmHg on 2 evaluations at least 10 minutes apart at screening.
Treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.
Previous treatment with EGT0001474.
Vaccination within 30 days prior to the first dose of study medication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mason W. Freeman, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
dgd Research Inc., a Cetero Research Company
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
2198430
Citation
Blondel O, Bailbe D, Portha B. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism. 1990 Aug;39(8):787-93. doi: 10.1016/0026-0495(90)90120-2.
Results Reference
background
PubMed Identifier
16732006
Citation
Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care. 2006 Jun;29(6):1263-8. doi: 10.2337/dc06-0062.
Results Reference
background
PubMed Identifier
18308683
Citation
American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Erratum In: Diabetes Care. 2008 Jun;31(6):1271.
Results Reference
background
PubMed Identifier
18165335
Citation
American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012. No abstract available.
Results Reference
background
PubMed Identifier
15624123
Citation
Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8. doi: 10.1002/dmrr.532.
Results Reference
background
PubMed Identifier
18356408
Citation
Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 Jun;57(6):1723-9. doi: 10.2337/db07-1472. Epub 2008 Mar 20.
Results Reference
background
PubMed Identifier
18705823
Citation
Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008 Aug;62(8):1279-84. doi: 10.1111/j.1742-1241.2008.01829.x.
Results Reference
background
PubMed Identifier
19129749
Citation
Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum In: Clin Pharmacol Ther. 2009 May;85(5):558.
Results Reference
background
PubMed Identifier
9392506
Citation
Krook A, Kawano Y, Song XM, Efendic S, Roth RA, Wallberg-Henriksson H, Zierath JR. Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes. 1997 Dec;46(12):2110-4. doi: 10.2337/diab.46.12.2110.
Results Reference
background
PubMed Identifier
10480610
Citation
Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800. doi: 10.2337/diabetes.48.9.1794.
Results Reference
background
PubMed Identifier
1740408
Citation
Pajor AM, Wright EM. Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem. 1992 Feb 25;267(6):3557-60.
Results Reference
background
PubMed Identifier
14569097
Citation
Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003 Nov;14(11):2873-82. doi: 10.1097/01.asn.0000092790.89332.d2.
Results Reference
background
PubMed Identifier
7201854
Citation
Toggenburger G, Kessler M, Semenza G. Phlorizin as a probe of the small-intestinal Na+,D-glucose cotransporter. A model. Biochim Biophys Acta. 1982 Jun 14;688(2):557-71. doi: 10.1016/0005-2736(82)90367-4.
Results Reference
background
PubMed Identifier
8814948
Citation
Tsujihara K, Hongu M, Saito K, Inamasu M, Arakawa K, Oku A, Matsumoto M. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo). 1996 Jun;44(6):1174-80. doi: 10.1248/cpb.44.1174.
Results Reference
background
Learn more about this trial
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
We'll reach out to this number within 24 hrs